Based on evidence from previous trials and our analyses, although both SGLT2 inhibitors seem to reduce the risk of heart failure, we consider that dapagliflozin may have greater effects on heart failure reduction compared to empagliflozin. Here, SLC5A2 is linked to heart failure.